97 related articles for article (PubMed ID: 16796486)
1. Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women.
Massad LS; Evans CT; Minkoff H; Watts DH; Greenblatt RM; Levine AM; Anastos K; Young M; Seifer DB; Golub E; Cohen M
J Womens Health (Larchmt); 2006 Jun; 15(5):591-8. PubMed ID: 16796486
[TBL] [Abstract][Full Text] [Related]
2. Effect of HIV-1 infection and increasing immunosuppression on menstrual function.
Ezechi OC; Jogo A; Gab-Okafor C; Onwujekwe DI; Ezeobi PM; Gbajabiamila T; Adu RA; Audu RA; Musa AZ; Salu OB; Meschack E; Herbertson E; Odunukwe N; Idigbe OE
J Obstet Gynaecol Res; 2010 Oct; 36(5):1053-8. PubMed ID: 21058440
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.
Silverberg MJ; Gore ME; French AL; Gandhi M; Glesby MJ; Kovacs A; Wilson TE; Young MA; Gange SJ
Clin Infect Dis; 2004 Sep; 39(5):717-24. PubMed ID: 15356788
[TBL] [Abstract][Full Text] [Related]
4. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
5. Contraceptive use among U.S. women with HIV.
Massad LS; Evans CT; Wilson TE; Golub ET; Sanchez-Keeland L; Minkoff H; Weber K; Watts DH
J Womens Health (Larchmt); 2007 Jun; 16(5):657-66. PubMed ID: 17627401
[TBL] [Abstract][Full Text] [Related]
6. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.
Ahdieh-Grant L; Li R; Levine AM; Massad LS; Strickler HD; Minkoff H; Moxley M; Palefsky J; Sacks H; Burk RD; Gange SJ
J Natl Cancer Inst; 2004 Jul; 96(14):1070-6. PubMed ID: 15265968
[TBL] [Abstract][Full Text] [Related]
7. A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants.
Navazesh M; Mulligan R; Barrón Y; Redford M; Greenspan D; Alves M; Phelan J;
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jun; 95(6):693-8. PubMed ID: 12789150
[TBL] [Abstract][Full Text] [Related]
8. Hormonal levels among HIV-1-seropositive women compared with high-risk HIV-seronegative women during the menstrual cycle. Women's Health Study (WHS) 001 and WHS 001a Study Team.
Cu-Uvin S; Wright DJ; Anderson D; Kovacs A; Watts DH; Cohn J; Landay A; Reichelderfer PS
J Womens Health Gend Based Med; 2000 Oct; 9(8):857-63. PubMed ID: 11074951
[TBL] [Abstract][Full Text] [Related]
9. The effect of highly active antiretroviral therapy on dermatologic disease in a longitudinal study of HIV type 1-infected women.
Maurer T; Rodrigues LK; Ameli N; Phanuphak N; Gange SJ; DeHovitz J; French AL; Glesby M; Jordan C; Khalsa A; Hessol NA
Clin Infect Dis; 2004 Feb; 38(4):579-84. PubMed ID: 14765353
[TBL] [Abstract][Full Text] [Related]
10. The influence of stress on the menstrual cycle among newly incarcerated women.
Allsworth JE; Clarke J; Peipert JF; Hebert MR; Cooper A; Boardman LA
Womens Health Issues; 2007; 17(4):202-9. PubMed ID: 17560123
[TBL] [Abstract][Full Text] [Related]
11. Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome.
Chirgwin KD; Feldman J; Muneyyirci-Delale O; Landesman S; Minkoff H
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):489-94. PubMed ID: 8757426
[TBL] [Abstract][Full Text] [Related]
12. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
13. Menstrual symptoms in women infected by the human immunodeficiency virus.
Shah PN; Smith JR; Wells C; Barton SE; Kitchen VS; Steer PJ
Obstet Gynecol; 1994 Mar; 83(3):397-400. PubMed ID: 8127532
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS).
Anastos K; Kalish LA; Palacio H; Benson CA; Delapenha R; Chirgwin K; Stonis L; Telzak EE
J Acquir Immune Defic Syndr; 1999 Jun; 21(2):141-7. PubMed ID: 10360806
[TBL] [Abstract][Full Text] [Related]
15. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus.
Massad LS; Silverberg MJ; Springer G; Minkoff H; Hessol N; Palefsky JM; Strickler HD; Levine AM; Sacks HS; Moxley M; Heather Watts D
Am J Obstet Gynecol; 2004 May; 190(5):1241-8. PubMed ID: 15167825
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
[TBL] [Abstract][Full Text] [Related]
18. Predictors of hysterectomy as a treatment for menstrual symptoms.
Graham M; James EL; Keleher H
Womens Health Issues; 2008; 18(4):319-27. PubMed ID: 18590884
[TBL] [Abstract][Full Text] [Related]
19. Influence of age and CD4+ T cell counts on the prevalence of genital human papillomavirus infection among HIV-seropositive men who have sex with men in Taiwan.
Cheng SH; Chu FY; Lin YS; Hsueh YM
J Med Virol; 2012 Dec; 84(12):1876-83. PubMed ID: 23080490
[TBL] [Abstract][Full Text] [Related]
20. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
